Page 7 - Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG

guideline: mCnPC & mCSPC

References 22. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive
prostate cancer: Long-term survival analysis of the randomized phase 3 E3805 CHAARTED trial. J Clin
Oncol 2018;36:1080-7. https://doi.org/10.1200/JCO.2017.75.3657
1. Committee CCSA. Canadian Cancer Statistics 2018. Canadian Cancer Society. 2019. 23. Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel vs. ADT alone in
2. Glass TR, Tangen CM, Crawford ED, et al. Metastatic carcinoma of the prostate: Identifying prognos- metastatic non-castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of
tic groups using recursive partitioning. J Urol 2003;169:164-9. https://doi.org/10.1016/S0022- the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70:256-62. https://doi.org/10.1016/j.
5347(05)64059-1 eururo.2015.11.005
3. Gravis G, Boher JM, Fizazi K, et al. Prognostic factors for survival in non-castrate metastatic prostate 24. Gravis G, Boher JM, Chen YH, et al. Burden of metastatic castrate-naive prostate cancer patients, to identify
cancer: Validation of the Glass model and development of a novel simplified prognostic model. Eur Urol men more likely to benefit from early docetaxel: Further analyses of CHAARTED and GETUG-AFU15 studies.
2015;68:196-204. https://doi.org/10.1016/j.eururo.2014.09.022 Eur Urol 2018;73:847-55. https://doi.org/10.1016/j.eururo.2018.02.001
4. Frees S, Akamatsu S, Bidnur S, et al. The impact of time to metastasis on overall survival in patients 25. Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden
with prostate cancer. World J Urol 2018;36:1039-46. https://doi.org/10.1007/s00345-018-2236-4 metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. Ann
5. Mosillo C, Iacovelli R, Ciccarese C, et al. De novo metastatic castration sensitive prostate cancer: Oncol 2019. [Epub ahead of print]. https://doi.org/10.1093/annonc/mdz396
State of art and future perspectives. Cancer Treat Rev 2018;70:67-74. https://doi.org/10.1016/j. 26. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone
ctrv.2018.08.005 in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final
6. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol
strength of recommendations. BMJ 2008;336:924-6. https://doi.org/10.1136/bmj.39489.470347. 2015;16:152-60. https://doi.org/10.1016/S1470-2045(14)71205-7
AD 27. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer.
7. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: An autopsy study of N Engl J Med 2011;364:1995-2005. https://doi.org/10.1056/NEJMoa1014618
1589 patients. Hum Pathol 2000;31:578-83. https://doi.org/10.1053/hp.2000.6698 28. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with
8. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate hormone therapy. N Engl J Med 2017;377:338-51. https://doi.org/10.1056/NEJMoa1702900
cancer. N Engl J Med 2015;373:737-46. https://doi.org/10.1056/NEJMoa1503747 29. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate
9. Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed cancer. N Engl J Med 2017;377:352-60. https://doi.org/10.1056/NEJMoa1704174
high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a 30. Hoyle AP, Ali A, James ND, et al. Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive
randomized, double-blind, phase 3 trial. Lancet Oncol 2019;20:686-700. https://doi.org/10.1016/ prostate cancer. Eur Urol 2019;76:719-28. https://doi.org/10.1016/j.eururo.2019.08.006
S1470-2045(19)30082-8 31. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemo-
10. Iacovelli R, Ciccarese C, Schinzari G, et al. Going towards a precise definition of the therapeutic manage- therapy. N Engl J Med 2014;371:424-33. https://doi.org/10.1056/NEJMoa1405095
ment of de novo metastatic castration-sensitive prostate cancer patients: How prognostic classification 32. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemo-
impact treatment decisions. Crit Rev Oncol Hematol 2019;139:83-6. https://doi.org/10.1016/j. therapy. N Engl J Med 2012;367:1187-97. https://doi.org/10.1056/NEJMoa1207506
critrevonc.2019.05.005 33. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate
11. Nair B, Wilt T, MacDonald R, et al. Early vs. deferred androgen suppression in the treatment of advanced cancer. N Engl J Med 2019;381:121-31. https://doi.org/10.1056/NEJMoa1903835
prostatic cancer. Cochrane Database Syst Rev 2002(1):CD003506. 34. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A randomized, phase 3 study of androgen-
12. Kunath F, Goebell PJ, Wullich B, et al. Timing of androgen deprivation monotherapy and combined deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate
treatments in castration-sensitive and castration-resistant prostate cancer: A narrative review. World J Urol cancer. J Clin Oncol 2019:JCO1900799. https://doi.org/10.1200/JCO.19.00799
2019. [Epub ahead of print]. https://doi.org/10.1007/s00345-019-02704-y 35. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N
13. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent vs. continuous androgen- Engl J Med 2019;381:13-24. https://doi.org/10.1056/NEJMoa1903307
deprivation: A systematic review of randomized trials. J Clin Oncol 2013;31:2029-36. https://doi. 36. Eriksson S, Eriksson A, Stege R, et al. Bone mineral density in patients with prostatic cancer treated
org/10.1200/JCO.2012.46.5492 with orchidectomy and with estrogens. Calcif Tissue Int 1995;57:97-9. https://doi.org/10.1007/
14. Aagaard K, Ma J, Antony KM, et al. The placenta harbors a unique microbiome. Sci Translat Med BF00298427
2014;6:237ra65. https://doi.org/10.1126/scitranslmed.3008599 37. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss
15. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumor for newly diagnosed, meta- in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-
static prostate cancer (STAMPEDE): A randomized, controlled, phase 3 trial. Lancet 2018;392:2353-66. 12. https://doi.org/10.1097/01.ju.0000063820.94994.95
https://doi.org/10.1016/S0140-6736(18)32486-3 38. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in
16. Burdett S, Boeve LM, Ingleby FC, et al. Prostate radiotherapy for metastatic hormone-sensitive pros- men receiving androgen-deprivation therapy for prostate cancer: A randomized trial. Ann Intern Med
tate cancer: A STOPCAP systematic review and meta-analysis. Eur Urol 2019;76:115-24. https://doi. 2007;146:416-24. https://doi.org/10.7326/0003-4819-146-6-200703200-00006
org/10.1016/j.eururo.2019.02.003 39. Egerdie B, Saad F. Bone health in the prostate cancer patient receiving androgen-deprivation therapy:
17. Sooriakumaran P. Testing radical prostatectomy in men with prostate cancer and oligometastases to the A review of present and future management options. Can Urol Assoc J 2010;4:129-35. https://doi.
bone: A randomized, controlled feasibility trial. BJU Int 2017;120:E8-E20. https://doi.org/10.1111/ org/10.5489/cuaj.811
bju.13925 40. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy
18. Rexer H. [Metastatic, hormone-naive prostate cancer interventional study: Multicenter, prospective, ran- for prostate cancer. N Engl J Med 2009;361:745-55. https://doi.org/10.1056/NEJMoa0809003
domized study to evaluate the effect of standard drug therapy with or without radical prostatectomy in 41. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women
patients with limited bone metastasized prostate cancer (G-RAMPP - the AUO AP 75/13 study)]. Urologe with osteoporosis: Results from the phase 3 randomized FREEDOM trial and open-label extension. Lancet
A 2015;54:1613-6. https://doi.org/10.1007/s00120-015-4020-z Diabetes Endocrinol 2017;5:513-23. https://doi.org/10.1016/S2213-8587(17)30138-9
19. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone 42. Bai H, Jing D, Guo A, et al. Randomized controlled trial of zoledronic acid for treatment of osteoporosis in
for advanced prostate cancer. N Engl J Med 2004;351:1502-12. https://doi.org/10.1056/ women. J Int Med Res 2013;41:697-704. https://doi.org/10.1177/0300060513480917
NEJMoa040720
20. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long- Correspondence: Dr. Alan So, Department of Urologic Sciences, University of British Columbia,
term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multi-arm,
multistage, platform randomized controlled trial. Lancet 2016;387:1163-77. https://doi.org/10.1016/ Vancouver, BC, Canada; alan.so@ubc.ca
S0140-6736(15)01037-5
21. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate
metastatic prostate cancer (GETUG-AFU 15): A randomized, open-label, phase 3 trial. Lancet Oncol
2013;1:149-58. https://doi.org/10.1016/S1470-2045(12)70560-0

CUAJ • February 2020 • Volume 14, Issue 2 23